Cited by 38Spinal Cord Injury ResearchNerve injury and regenerationMultiple Sclerosis Research Studies

The cancer drug tamoxifen: A potential therapeutic treatment for spinal cord injury

Open access
Guptarak, Jutatip, Wiktorowicz, John E., Sadygov, Rovshan G., Zivadinovic, Dragoslava, Paulucci-Holthauzen, Adriana A., Vergara, Leoncio, Nesic, Olivera·2014·Journal of Neurotrauma

Abstract

Tamoxifen (TMX) is a selective estrogen receptor modulator that can mimic the neuroprotective effects of estrogen but lacks its systemic adverse effects. We found that TMX (1 mg/day) significantly improved the motor recovery of partially paralyzed hind limbs of male adult rats with thoracic spinal cord injury (SCI), thus indicating a translational potential for this cancer medication given its clinical safety and applicability and the lack of currently available treatments for SCI. To shed light on the mechanisms underlying the beneficial effects of TMX for SCI, we used proteomic analyses, Western blots and histological assays, which showed that TMX treatment spared mature oligodendrocytes/increased myelin levels and altered reactive astrocytes, including the upregulation of the water channels aquaporin 4 (AQP4), a novel finding. AQP4 increases in TMX-treated SCI rats were associated with smaller fluid-filled cavities with borders consisting of densely packed AQP4-expressing astrocytes that closely resemble the organization of normal glia limitans externa (in contrast to large cavities in control SCI rats that lacked glia limitans-like borders and contained reactive glial cells). Based on our findings, we propose that TMX is a promising candidate for the therapeutic treatment of SCI and a possible intervention for other neuropathological conditions associated with demyelination and AQP4 dysfunction.

Integrity signals

Registry

Crossref · 10.1089/neu.2013.3108

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Guptarak, J., Wiktorowicz, J. E., Sadygov, R. G., Zivadinovic, D., Paulucci-Holthauzen, A. A., Vergara, L., & Nesic, O.
Affiliations
  • The University of Texas Medical Branch at Galveston (US)
  • University of Texas Medical Branch
Venue
Journal of Neurotrauma
Published
2014-02
Volume
31
Issue
3
Pages
268-283
ISSN
  • 0897-7151 (ISSN-L)
  • 1557-9042
OpenAlex
W1965323887
Cited by
38
References
72
Citations by year
2026: 2 · 2025: 1 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 9 · 2015: 5 · 2014: 2
FWCI
3.99
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurotrauma (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eCommons - AKU (Aga Khan University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Spinal Cord Injury Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
tamoxifen, spinal cord injury, selective estrogen receptor modulators, motor recovery, oligodendrocytes, myelin, reactive astrocytes, aquaporin-4, demyelination, hindlimb paralysis, neuroprotection
MeSH terms
Animals, Brain, Fluorescent Antibody Technique, Male, Spinal Cord Injuries, Tamoxifen, Blotting, Western, Rats, Sprague-Dawley, Neuroprotective Agents, Recovery of Function, Proteomics, Rats, Aquaporin 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review